| Company/Division name | Zaara Biotech USA |
| Parent company | Zaara Biotech |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2022 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | India |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | algal seaweed technology |
| What non-domestic negative factors made offshoring less attractive? | Green considerations |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Government Incentives, $10 Mn from the UAE-based TCN International Commer |
